NCT02341326Completed
Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD
Source: ClinicalTrials.gov · Last updated 11 Mar 2025
Brief summary (registry, in English)
Early changes associated with the development of smoking-induced diseases, e.g., COPD and lung cancer (the two commonest causes of death in U.S.) are often characterized by abnormal airway epithelial differentiation. Airway basal cells (BC) are stem/progenitor cells necessary for generation of differentiated airway epithelium. Based on our preliminary observations on SAE BC cells and FGFR2 signaling, we hypothesized that suppression of FGFR2 signaling in the SAE BC stem/progenitor cells by cigarette smoking renders these cells less potent in generating and maintaining normally differentiated SAE, shifting these cells towards a COPD associated phenotype. To test this, SAE basal cells will be isolated from cultured cells obtained through bronchoscopic brushings and analyzed through in vitro assays for their stem/progenitor capacities.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 111 (actual)
- First submitted
- 16 Jul 2014
- Start date
- Jul 2014
- Primary completion date
- 29 Oct 2024
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- COPD
- NCT number
- NCT02341326
What you commit to
- Study type: Observational
- Participants enrolled: 111
- From Jul 2014 to the primary completion date, 29 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current alcohol or drug abuse
Other illness
- Current active infection or acute illness of any kind
- Evidence of malignancy within the past 5 years
Other
- Unable to meet the inclusion criteria
- Pregnancy
Who the study is looking for
- Must be capable of providing informed consent
- Males and females, age 18 or older
- Nonsmoking, matched with other groups by age, sex, ethnic/racial group
- Good overall health without history of chronic lung disease, including asthma, and without recurrent or recent (within 3 months) acute pulmonary disease
- Normal physical examination
- Normal routine laboratory evaluation, including general hematologic studies, general serologic/ immunologic studies, general biochemical analyses, and urine analysis
- Negative HIV serology
- Normal chest X-ray (PA and lateral)
- Normal electrocardiogram
- Females - not pregnant
- No history of allergies to medications to be used in the bronchoscopy procedure
- Not taking any medications relevant to lung disease or having an effect on the airway epithelium
- Willingness to participate in the study
Criteria the registry did not label
- Samples from newly recruited research subjects will be collected under the IRB approved protocol "Collection of Airway, Blood and/or Urine Specimens from Subjects for Research Studies" (IRB # 1204012331) or may have been collected under previous IRB approved collection protocols: #0005004439, #0005004440, and #0905010391.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.